We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Roughly 70 percent of adults would feel more comfortable taking a drug that has been on the market for a decade or more than a newer drug, according to a new survey by Medco Health Solutions that indicates recent safety issues are taking a toll on the public’s perception of drugs.
State lawmakers have introduced more than 500 separate bills and resolutions affecting the pharmaceutical industry, including proposals to establish clinical trial requirements and lower Rx spending through generic drug use and preferred drug lists, according to a new report.
Two Democratic senators have asked HHS Secretary Michael Leavitt to launch an investigation into reports that a conservative member of an FDA advisory committee was asked to write a “minority report” explaining why the agency should reject OTC status for the emergency contraceptive Plan B.
Seven out of 10 adults would prefer to take a drug that has been on the market for a decade or more compared to a newer drug, according to a new survey by Medco Health Solutions that indicates recent safety issues are taking a toll on the public’s perception of drugs.
A House panel that oversees drug safety issues plans to widen its investigation into the pharmaceutical industry’s promotional practices — the latest indication that momentum is building in Congress for FDA drug safety reform legislation, observers say.
Pharmaceutical firms not only have to worry about counterfeiters taking a chunk out of their bottom lines, but they must also protect themselves from being held liable for those bogus products, according to an expert on the counterfeit drug trade.
The House Democratic leadership has unveiled a healthcare agenda that includes measures to allow the HHS to negotiate drug prices under the Medicare prescription drug benefit and legalize the importation of prescription drugs.
Leading House Democrats have unveiled a healthcare agenda that includes measures to legalize the importation of prescription drugs and allow the HHS to negotiate the prices of drugs under the Medicare prescription drug benefit.
Democratic lawmakers have stepped up their opposition to a provision in the Central America Free Trade Agreement (CAFTA) that gives pharmaceutical firms five years of market exclusivity on brand drugs approved in member countries.